

Table S1. Disease progression in 352 patients with COVID-19 ^a

Clinical classifications at admission	Final classifications during the treatment			
	Mild/moderate	Severe	Critical	Total
Mild/moderate	282	18 (1) ^b	1	301
Severe	0	17	31 (14, 15) ^b	48
Critical	0	0	3	3
Total	282	35	35	352

^a P < 0.001 for the McNemar test.

^b One shock occurred in the 18 severe patients who progressed from mild/moderate, while 14 shocks and 15 deaths occurred among the 31 critical patients who developed from severe conditions.

Table S2 Hazard ratios for serious clinical outcomes among COVID-19 patients with a neutrophil to lymphocyte ratio ≥ 2.6937 compared with those of < 2.6937

Disease progression	Hazard Ratio (95% confidence interval)	
	Unadjusted	Adjusted ^a
Deterioration	5.4 (2.6-11.1)	4.1 (1.9-8.8)
Shock	21.2 (2.8-161.3)	13.1 (1.7-102.3)
Death	19.8 (2.6-151.4)	11.3 (1.4-89.1)

^a Age (< or ≥ 60 years), sex (male or female), smoking (yes or no), drinking (yes or no), clinical classifications at admission (mild/moderate, severe, or critical) and history of chronic diseases (yes or no) were included in the adjusted model.






Figure S1.

